33 related articles for article (PubMed ID: 11109253)
21. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.
Coukell AJ; Brogden RN
Drugs; 1998 Apr; 55(4):585-612. PubMed ID: 9561346
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical design of the liposomal antimicrobial agents for infectious disease.
Moribe K; Maruyama K
Curr Pharm Des; 2002; 8(6):441-54. PubMed ID: 12069381
[TBL] [Abstract][Full Text] [Related]
23. Lipid formulation as a drug carrier for drug delivery.
Tomii Y
Curr Pharm Des; 2002; 8(6):467-74. PubMed ID: 12069383
[TBL] [Abstract][Full Text] [Related]
24. Liposomal amphotericin B bases of therapeutic index increase.
Legrand P; Vertut-Doï A; Bolard J
Biomater Artif Cells Immobilization Biotechnol; 1993; 21(3):407-13. PubMed ID: 8399981
[TBL] [Abstract][Full Text] [Related]
25. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
Tiphine M; Letscher-Bru V; Herbrecht R
Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
[TBL] [Abstract][Full Text] [Related]
26. The use of lipid formulations of amphotericin B for systemic fungal infections.
Leenders AC; de Marie S
Leukemia; 1996 Oct; 10(10):1570-5. PubMed ID: 8847891
[TBL] [Abstract][Full Text] [Related]
27. Liposomes as potential carrier system for targeted delivery of polyene antibiotics.
Naik SR; Desai SK; Shah PD; Wala SM
Recent Pat Inflamm Allergy Drug Discov; 2013 Sep; 7(3):202-14. PubMed ID: 23745986
[TBL] [Abstract][Full Text] [Related]
28. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
Chakraborty KK; Naik SR
Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
[TBL] [Abstract][Full Text] [Related]
29. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
Rust DM; Jameson G
Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
[TBL] [Abstract][Full Text] [Related]
30. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
31. Liposomal and lipid-based formulations of amphotericin B.
de Marie S
Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
[TBL] [Abstract][Full Text] [Related]
32. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.
Takemoto K; Kanazawa K
J Liposome Res; 2017 Sep; 27(3):186-194. PubMed ID: 27328721
[TBL] [Abstract][Full Text] [Related]
33. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.
Brogden RN; Goa KL; Coukell AJ
Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
